Anterogen Co Ltd
Anterogen Co Ltd is a South Korean biopharmaceutical company focused on the development and commercialization of cell therapy products, including allogeneic mesenchymal stem cells for orthopedic and autoimmune diseases.
Business. Anterogen Co Ltd (065660.KQ) is a pharmaceutical company engaged in the pharmaceuticals and medical research industry. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Anterogen Co Ltd (065660.KQ) is a pharmaceutical company engaged in the pharmaceuticals and medical research industry. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Anterogen maintains a strong liquidity position with a current ratio of 78.12, indicating that its current assets significantly exceed its current liabilities. The company holds KRW 1.58 billion in cash and equivalents, and it has no long-term debt, which supports its liquidity profile. However, the company reported negative operating and free cash flows of KRW -1.02 billion and KRW -1.05 billion, respectively, suggesting ongoing cash burn.
Profitability metrics are negative, with a return on equity (ROE) of -1.57% and a return on assets (ROA) of -1.56%, indicating that the company is not generating returns for its shareholders or asset base. These figures are below the typical thresholds for profitability in the biotechnology industry, where companies often trade at a loss during early development phases.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regulatory or market disruptions in its primary market.
Looking ahead, the company is expected to continue experiencing negative operating performance, with no clear indication of a near-term turnaround in its financial trajectory. The absence of positive revenue growth or margin expansion in the most recent financial period suggests that the company is still in a development or scaling phase, which is common for biotechnology firms.
Risk factors for Anterogen include its reliance on a limited product portfolio and the absence of long-term debt, which, while reducing financial leverage, also limits its ability to scale through external financing. The company has not issued any dilutive shares in the recent period, and no dilution risks were identified in the risk assessment. However, the continued negative cash flows may necessitate future capital raises, which could lead to share dilution.
Recent filings and transcripts do not indicate any major strategic shifts or new product approvals. The company remains focused on its core cell therapy pipeline, with no significant new partnerships or regulatory milestones disclosed in the latest available data.
- Anterogen has a strong liquidity position with a current ratio of 78.12 and no long-term debt.
- The company is not currently profitable, with negative ROE and ROA of -1.57% and -1.56%, respectively.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company is expected to continue experiencing negative cash flows and operating losses in the near term.
- No immediate dilution or liquidity risks were identified, but future capital raises may be necessary to fund operations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Anterogen Co Ltd Market data — financials · 2026-05-26